As pundits speculated about market turbulence that might dock IPOs, calm waters allowed three to price: Wave Life Sciences Ltd., with preclinical nucleic acid therapeutics bound for trials next year, sold about 6.37 million shares at $16 each to raise $102 million. Voyager Therapeutics Inc., moving along a partnered gene-therapy Parkinson’s disease (PD) candidate that has reached the phase I stage, also entered the IPO ring, dispensed 5 million shares at $14 each to collect $70 million. They were followed closely by radiopharmaceuticals-focused Advanced Accelerator Applications S.A. (AAA), which placed about 4.68 million American depositary shares that represent about 9.37 million ordinary shares at $16 each, for proceeds of about $75 million.

Doing well in its debut, Saint-Genis-Pouilly, France-based AAA (NASDAQ:AAAP) closed Wednesday at $24.32, up $8.32, or 52 percent. Voyager (NASDAQ:VYGR), of Cambridge, Mass., ended at $16.30, up $2.30, or 16 percent, and Wave (NASDAQ:WVE), also of Cambridge, finished at $16.94, up 94 cents.

In February – about a year after notching its $45 million series A round – Voyager inked a pact that could be worth as much as $845 million with Paris-based Sanofi SA unit Genzyme, to discover, develop and commercialize gene therapies for severe central nervous system disorders. The pair is combining Voyager’s adeno-associated virus approach with Genzyme’s scientific prowess in gene therapy, taking aim at breakthrough therapies in a range of indications, including programs for PD, Friedreich’s ataxia (FA), Huntington’s disease (HD) and others. The collaboration mixes programs and intellectual property from both companies. (See BioWorld Today, Feb. 12, 2015.)

Voyager is taking care of research and development in the Genzyme deal, with the latter owning an option to license ex-U.S. rights for several programs after proof-of-concept human trials are done. U.S. rights stay with Voyager to its lead programs in PD (VY-AADC01) and FA (VY-FXN01) and will split U.S. profits with Genzyme for an HD program (VY-HTT01). VY-AADC01 in PD is farthest along. Voyager kept global rights to its lead program in amyotrophic lateral sclerosis (VY-SOD101), excluded from the deal that brought $100 million up front with the rest in potential milestone payments.

In the IPO, expected to close next Monday, Voyager granted the underwriters a 30-day option to purchase up to 750,000 more shares to cover overallotments, if any. Cowen and Co. and Piper Jaffray & Co. are acting as joint book-running managers for the offering, with Wedbush Pacgrow and Nomura serving as co-managers.

AAA in September disclosed results from its pivotal phase III Netter study with Lutathera (177Lu-dotatate), which met its primary endpoint of assessing progression-free survival (PFS), showing that Lutathera significantly improved PFS when compared with Sandostatin LAR 60 mg (octreotide LAR, Novartis AG) in patients with advanced mid-gut neuroendocrine tumors. Lutathera, a peptide receptor radionuclide therapy, is described more specifically as a Lu-177-labeled somatostatin analog peptide.

In the IPO, AAA granted the underwriters a 30-day option to buy up to 703,200 more ADSs from the company. Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering, with Canaccord Genuity Inc. and JMP Securities LLC serving as co-managers.

Wave Life Sciences’ nucleic-acid platform is designed to sort out the problem in that research field of stereoisomers, some of which bring therapeutic effects, while others don’t and may cause side effects, which makes putting two or more of them together problematic. Rationally designed, the firm’s “stereopure” candidates are said to precisely target underlying disease biology for better activity, stability, specificity and immunogenicity. Everything is preclinical so far, with programs in HD and Duchenne muscular dystrophy. Clinical development is expected to start late next year and early in 2017, Wave said.

As part of the IPO, the company granted underwriters a 30-day option to purchase up to an additional 956,250 ordinary shares. Jefferies and Leerink Partners are acting as joint book-running managers for the offering, with JMP Securities and SunTrust Robinson Humphrey in the roles of co-managers.